Clinical Trial: Phase II/III Study of FXS5626 in Participants With Non-segmental Vitiligo

U.S., Sept. 26 -- ClinicalTrials.gov registry received information related to the study (NCT07840820) titled 'Phase II/III Study of FXS5626 in Participants With Non-segmental Vitiligo' on Sept. 17.

Brief Summary: This is a multicenter, randomized, double-blind, placebo-controlled, adaptive seamless design, Phase II/III study evaluating the efficacy and safety of FXS5626 in participants with non-segmental vitiligo.

Study Start Date: Oct. 30

Study Type: INTERVENTIONAL

Condition: Non-segmental Vitiligo

Intervention: DRUG: Intervention1: FXS5626 Tablets

FXS5626 tablets administered orally twice daily (BID) for 24 weeks.

DRUG: Intervention2: FXS5626 Tablets

FXS5626 tablets administered orally twice daily (BID) for 24 weeks.

DRUG: Inte...